Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 24INDUSTRY 11NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neuroblastoma 1

Interventions

Gemcitabine 17Fluorouracil 8Capecitabine 6Radiotherapy 5Leucovorin 5Albumin-Bound Paclitaxel 5Taxes 4Irinotecan 4Cisplatin 4130-nm albumin-bound paclitaxel 4Specimen Handling 3Radiotherapy, Conformal 3Docetaxel 3irinotecan sucrosofate 2dehydroftorafur 2Surgical Procedures, Operative 2Radiosurgery 2Pancreaticoduodenectomy 2Chemotherapy, Adjuvant 2Cetuximab 2trametinib 1tipifarnib 1saracatinib 1pegfilgrastim 1lanreotide 1ganitumab 1durvalumab 1conatumumab 1beta-D-glucosylisophosphoramide mustard 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Pancreatic Neoplasms × irinotecan sucrosofate × Clear all
NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network

Phase 3 Recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
176 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡